An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
暂无分享,去创建一个
M. Kattan | C. Parker | S. Nilsson | O. Sartor | S. Wilhelm | N. Vogelzang | M. Shan | J. O’Sullivan | R. Coleman | Ø. Bruland | D. Heinrich | S. Helle | Chris Parker | S. Kobina | L. Xu | Sten Nilsson | J. O'Sullivan | Daniel Heinrich | Oø Bruland | J. O’Sullivan | C. Parker
[1] Adam T Froemming,et al. Prostate cancer post-treatment follow-up and recurrence evaluation , 2016, Abdominal Radiology.
[2] P. Kantoff,et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] M. Carducci,et al. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. , 2015, European urology.
[4] Tomasz Burzykowski,et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Vessella,et al. Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumour and tumour-induced bone growth in two osteoblastic prostate cancer models , 2015 .
[6] R. Fitzgerald,et al. Revision of the NIST Standard for 223Ra: New Measurements and Review of 2008 Data , 2015, Journal of research of the National Institute of Standards and Technology.
[7] S. Fosså,et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.
[8] M. Morris,et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Armstrong,et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. , 2013, Journal of the National Cancer Institute.
[10] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[11] E. Alhoniemi,et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. , 2013, Journal of the National Cancer Institute.
[12] C. Parker,et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. , 2013, European urology.
[13] T. Ichikawa,et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis , 2012, International journal of urology : official journal of the Japanese Urological Association.
[14] I. Tannock,et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. , 2012, Urologic oncology.
[15] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.
[16] F. Saad,et al. Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.
[17] C. Tangen,et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.
[18] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Flandre,et al. Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997) , 1999 .
[21] S M Larson,et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.